The combination of anti-EpCAM-moAbs and anti-FRα-moAbs showed a significantly increased positive rate of CTC detection in ovarian cancer patients compared with anti-EpCAM-moAbs alone [216]. Here, EPCAM is linked to ovarian cancer.